AR033157A1 - Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer - Google Patents
Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancerInfo
- Publication number
- AR033157A1 AR033157A1 ARP020101347A ARP020101347A AR033157A1 AR 033157 A1 AR033157 A1 AR 033157A1 AR P020101347 A ARP020101347 A AR P020101347A AR P020101347 A ARP020101347 A AR P020101347A AR 033157 A1 AR033157 A1 AR 033157A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- fapaalfa
- bibh1
- alfa
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
El uso terapéutico de un anticuerpo humanizado que se une específicamente a la molécula conocida como FAPalfa. El anticuerpo, conocido como BIBH 1, tiene una semivida muy corta y cuando está marcado con un marcador terapéutico, es eficaz para tratar tumores malignos tales como el cáncer colorrectal y el cáncer de pulmon de células no pequenas. Se describen diferentes modos de usar el anticuerpo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28386801P | 2001-04-12 | 2001-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033157A1 true AR033157A1 (es) | 2003-12-03 |
Family
ID=23087909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101347A Withdrawn AR033157A1 (es) | 2001-04-12 | 2002-04-12 | Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer |
Country Status (4)
Country | Link |
---|---|
US (1) | US20030103968A1 (es) |
AR (1) | AR033157A1 (es) |
PE (1) | PE20021080A1 (es) |
WO (1) | WO2002083171A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894234A (zh) * | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7723344B2 (en) * | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102134230B (zh) | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
AU2005259992A1 (en) * | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1784645A2 (en) * | 2004-07-29 | 2007-05-16 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with fibroblast activation protein |
EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102935081B (zh) * | 2005-09-14 | 2015-03-04 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
SI1942898T2 (sl) | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ES2393372T3 (es) * | 2006-06-21 | 2012-12-20 | The Scripps Research Institute | Composición de ADN contra el antígeno tumoral estromal FAP y métodos de utlización de la misma |
PT2073810E (pt) * | 2006-09-13 | 2011-09-30 | Takeda Pharmaceutical | Utilização de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo- 3,4-di-hidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo para tratamento de diabetes, cancro, distúrbios auto-imunes e infecção por vih |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
ES2401536T3 (es) | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
CA2748449A1 (en) * | 2008-12-27 | 2010-07-15 | Pawan Saharan | Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof |
WO2014167083A1 (en) | 2013-04-12 | 2014-10-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
CN109796532A (zh) | 2017-11-17 | 2019-05-24 | 科济生物医药(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2023125796A1 (en) * | 2021-12-30 | 2023-07-06 | Concept To Medicine Biotech Co., Ltd. | Human antibodies against fap-alpha |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
AU2001256325A1 (en) * | 2000-03-17 | 2001-09-24 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
DE10045591A1 (de) * | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
-
2002
- 2002-04-10 PE PE2002000296A patent/PE20021080A1/es not_active Application Discontinuation
- 2002-04-11 US US10/121,464 patent/US20030103968A1/en not_active Abandoned
- 2002-04-11 WO PCT/EP2002/004041 patent/WO2002083171A2/en not_active Application Discontinuation
- 2002-04-12 AR ARP020101347A patent/AR033157A1/es not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20030103968A1 (en) | 2003-06-05 |
WO2002083171A2 (en) | 2002-10-24 |
PE20021080A1 (es) | 2003-02-12 |
WO2002083171A3 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033157A1 (es) | Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer | |
ES2141128T3 (es) | Combinacion de agentes anti-hormonales y moleculas de fijacion. | |
CY1117031T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
AR033978A1 (es) | Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas | |
CY1111379T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση πρωτογενων και μεταστατικων-νεοπλασματικων ασθενειων με τη χρηση τριοξειδιου του αρσενικου | |
CY1109525T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
ATE355079T1 (de) | Behandlung von prostata-krebs mit anti-erbb2 antikörpern | |
BRPI0213223B8 (pt) | polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição | |
PT1315520E (pt) | Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas | |
BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
TR200202183T2 (tr) | Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları | |
BR0210550A (pt) | Método para realçar a eficácia de terapias contra o câncer | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
ATE473279T1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
EE200300467A (et) | Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil | |
CY1106525T1 (el) | ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ | |
MXPA04007443A (es) | Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas. | |
UY27253A1 (es) | Uso del anticuerpo específico bibh1 de la proteína de activación de fibroblastos (fap) en el tratamiento del cáncer | |
ES2162167T3 (es) | Utilizacion de phmb para el tratamiento de enfermedades tumorales. | |
ATE419861T1 (de) | Peptide mit homing für lymphgefässtumor und ihre verwendung | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |